Flu and Covid jabs safe to be given at same time, study finds

Clinical trial on joint flu, Pfizer and AstraZeneca vaccinations reported only mild to moderate side-effectsCoronavirus – latest updatesSee all our coronavirus coverageFlu jabs are safe to give at the same time as the Pfizer or AstraZeneca Covid vaccines, according to the first clinical trial to investigate co-administering the shots in a single appointment.While some people experienced more side-effects with certain combinations of flu and Covid shots, the ailments were mainly mild to moderate, the study found. The most common side effects included pain at the injection site and temporary fatigue, headache or muscle pain.Continue reading...
Source: Guardian Unlimited Science - Category: Science Authors: Tags: Vaccines and immunisation Medical research Coronavirus UK news NHS Health Science Source Type: news

Related Links:

Since the emergence of the COVID-19 pandemic, Johnson &Johnson (the Company) has been closely monitoring newly emerging COVID-19 variants. In collaboration with academic groups in South Africa and around the world, the Company has been evaluating the effectiveness of its COVID-19 vaccine across variants, including now the new and rapidly spreading Omicron variant. The Company is testing blood serum from participants in completed and ongoing booster studies to look for neutralizing activity against the Omicron variant. In addition, the Company is pursuing an Omicron-specific variant vaccine and will progress it as neede...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
This study aims at estimating the prevalence of severe adverse events (SAEs) and their associated factors among health professionals vaccinated with ChAdOx1 nCoV-19 vaccine in Togo.MethodsA cross-sectional study was conducted from March 13th to 19th, 2021 in Togo among health professionals who received the first dose of the vaccine. An online self-administered questionnaire was used to collect sociodemographic and vaccination data. SAEs were defined as one resulting in hospitalization, medical consultation, or inability to work the day following the administration of the vaccine. Data analysis were performed using R ©...
Source: Archives of Public Health - Category: International Medicine & Public Health Source Type: research
CONCLUSION: BNT162b2 vaccination was tolerable among adults who were ≥ 75 years of age.PMID:34811980 | DOI:10.3346/jkms.2021.36.e318
Source: Journal of Korean Medical Science - Category: Biomedical Science Authors: Source Type: research
The objective of this retrospective cross-sectional study was to generate real-world multiple sclerosis–specific vaccine safety information, particularly in the context of specific DMTs, and provide information to mitigate specific concerns in vaccine hesitant PwMS. Methods Between 3/2021 and 6/2021, participants in iConquerMS, an online people-powered research network, reported SARS-CoV-2 vaccines, experiences of local (itch, pain, redness, swelling, or warmth at injection site) and systemic (fever, chills, fatigue, headache, joint pain, malaise, muscle ache, nausea, allergic, and other) reactions within 24 hours (...
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Tags: Public health, Multiple sclerosis, All epidemiology Article Source Type: research
NEW BRUNSWICK, N.J., October 21, 2021 – Johnson &Johnson (the Company) today announced that the U.S. Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP), has recommended its COVID-19 vaccine as a booster for all eligible individuals who receive an authorized COVID-19 vaccine. “Today’s recommendation supports the use of the Johnson &Johnson COVID-19 vaccine as a booster for eligible individuals in the U.S. regardless of which vaccine they initially receive,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
NEW BRUNSWICK, N.J., October 20, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for a booster dose of the Johnson &Johnson COVID-19 vaccine for adults aged 18 and older at least two months following primary vaccination with single-shot Johnson &Johnson COVID-19 vaccine; and for eligible individuals who received a different authorized or approved COVID-19 vaccine. The Johnson &Johnson booster shot will be the same formulation and dosage as the primary shot. The EUA follows a unanimous recommendat...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Latest News Source Type: news
NEW BRUNSWICK, N.J., October 15, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted 19-0 to recommend Emergency Use Authorization (EUA) for a booster dose of the Johnson &Johnson COVID-19 vaccine for adults aged 18 and older at least two months following initial vaccination with the single-shot vaccine. The vote was based on findings from two Company clinical trials, including the Phase 3 ENSEMBLE 2 study, which evaluated a booster dose of the Johnson &J...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
CONCLUSIONS: CoronaVac SARS-COV-2 vaccine has several mild symptoms of AEFI and not correlated with gender. Nevertheless, follow-up after vaccination is needed to prevent immunologic responses that may occur in some patients.PMID:34641944 | DOI:10.1186/s40360-021-00528-4
Source: BMC Pharmacology and Toxicology - Category: Drugs & Pharmacology Authors: Source Type: research
More News: AstraZeneca | Clinical Trials | Coronavirus | COVID-19 | Headache | Migraine | Pain | Pfizer | Research | Science | Study | Vaccines